alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Federal Register Volume 75, Number 44 (Monday, March 8, 2010)]
[Notices]
[Page 10551]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4863]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board

[STB Ex Parte No. 670 (Sub-No. 1)]

Notice of Rail Energy Transportation Advisory Committee Meeting

AGENCY: Surface Transportation Board.

ACTION: Notice of Rail Energy Transportation Advisory Committee 
Meeting.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given of a meeting of the Rail Energy 
Transportation Advisory Committee (RETAC), pursuant to section 10(a)(2) 
of the Federal Advisory Committee Act, Public Law No. 92-463, as 
amended (5 U.S.C., App. 2).

DATES: The meeting will be held on Tuesday, March 23, 2010, beginning 
at 2 p.m., E.D.T.

ADDRESSES: The meeting will be held in the Hearing Room on the first 
floor of the Surface Transportation Board's headquarters at Patriot's 
Plaza, 395 E Street, SW., Washington, DC 20423-0001.

FOR FURTHER INFORMATION CONTACT: Scott M. Zimmerman (202) 245-0202. 
Assistance for the hearing impaired is available through the Federal 
Information Relay Service (FIRS) at: (800) 877-8339.

SUPPLEMENTARY INFORMATION: RETAC arose from a proceeding instituted by 
the Board, in Establishment of a Rail Energy Transportation Advisory 
Committee, STB Ex Parte No. 670. RETAC was formed to provide advice and 
guidance to the Board, and to serve as a forum for discussion of 
emerging issues regarding the transportation by rail of energy 
resources, particularly, but not necessarily limited to, coal, ethanol, 
and other biofuels. The purpose of this meeting is to continue 
discussions regarding issues such as rail performance, capacity 
constraints, infrastructure planning and development, and effective 
coordination among suppliers, carriers, and users of energy resources. 
Potential agenda items include updates from the RETAC subcommittees 
(Best Practices, Capacity Planning, Communication, and Performance 
Measures), a briefing by the Energy Information Administration on its 
Annual Energy Outlook 2010, and a briefing by Christensen Associates on 
its updated study of competition in the railroad industry.
    The meeting, which is open to the public, will be conducted 
pursuant to RETAC's charter and Board procedures. Further 
communications about this meeting may be announced through the Board's 
Web site at http://www.stb.dot.gov.
    This action will not significantly affect either the quality of the 
human environment or the conservation of energy resources.

    Authority: 49 U.S.C. 721, 49 U.S.C. 11101; 49 U.S.C. 11121.

    Decided: March 3, 2010.

    By the Board, Rachel D. Campbell, Director, Office of 
Proceedings.
Jeffrey Herzig,
Clearance Clerk.
[FR Doc. 2010-4863 Filed 3-5-10; 8:45 am]
BILLING CODE 4915-01-P
```
CONFORMED

                       Securities and Exchange Commission
                             Washington, D.C. 20549

                                    FORM 6-K

                            Report of Foreign Issuer
                        Pursuant To Rule 13a-16 or 15d-16
                     of The Securities Exchange Act of 1934

For the month of February, 2003                   Commission File Number 1-12090

                        GRUPO RADIO CENTRO, S.A. de C.V.
                 (Translation of Registrant's name into English)

                           Constituyentes 1154, Piso 7
                       Col. Lomas Altas, Mexico D.F. 11954
                          (Address of principal office)

      (Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.)

(Check One) Form 20-F |X| Form 40-F |_|

      (Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)

(Check One) Yes |_| No |X|

      (If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b). 82-__.)
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                       Grupo Radio Centro, S.A. de C.V.
                                       (Registrant)

Date: February 27, 2003                By:  /s/ Pedro Beltran Nasr
                                          --------------------------------------
                                          Name:  Pedro Beltran Nasr
                                          Title: Chief Financial Officer
#### Lena B. Lensey *v.*Frederick D. Adametz et al. Francis M. Harvey *v.*Edward F. Becker et al.

*Richard T. O’Connell,*for the appellee (plaintiff in the second case and defendant Harvey in the first case).

*Harry W. Edelberg,*for the appellee (named defendant) in the first case.

*Joseph J. McOuinness,*for the appellants (defendants) in the second case.

Argued October 7

decided October 7, 1969

Pursuant to the motion dated June 13,1969, in the above-entitled consolidated cases, the judgment rendered therein is set aside, and the cases are remanded to the Superior Court in Middlesex County with direction to proceed according to law under the rule of *Harbor Construction Corporation*v. *D. V. Frione & Co.,*158 Conn. 14, 16, 255 A.2d 823.
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                         732,721
<SECURITIES>                                         0
<RECEIVABLES>                               27,689,356
<ALLOWANCES>                                   823,000
<INVENTORY>                                 28,937,387
<CURRENT-ASSETS>                            64,802,503
<PP&E>                                       6,609,160
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              71,743,654
<CURRENT-LIABILITIES>                       24,917,854
<BONDS>                                              0
<COMMON>                                        70,254
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                  46,755,546
<TOTAL-LIABILITY-AND-EQUITY>                71,743,654
<SALES>                                    125,168,578
<TOTAL-REVENUES>                           125,168,578
<CGS>                                       69,280,759
<TOTAL-COSTS>                               69,280,759
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             350,651
<INCOME-PRETAX>                              2,427,954
<INCOME-TAX>                                 (380,372)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 2,808,326
<EPS-PRIMARY>                                      .40
<EPS-DILUTED>                                      .40
        

</TABLE>
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1360 Trace microsphere. ( a ) *Identification.* A trace microsphere is a radioactively tagged nonbiodegradable particle that is intended to be injected into an artery or vein and trapped in the capillary bed for the purpose of studying blood flow within or to an organ.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any trace microsphere that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a trace microsphere that was in commercial distribution before May 28, 1976. Any other trace microsphere shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[45 FR 7907, Feb. 5, 1980, as amended at 52 FR 17736, May 11, 1987; 61 FR 50706, Sept. 27, 1996]
§ 876.5012 Biliary stent, drain, and dilator accessories. ( a ) *Identification.* Biliary stent, drain, and dilator accessories are manual devices that aid in the introduction and connection of biliary stents, drains, or dilators. This generic type of device includes the guiding catheter, pushing catheter, pigtail straightener, flap protector, nasal transfer tube, and drainage connecting tube.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[84 FR 14870, Apr. 12, 2019]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4022 Hydrogel wound dressing and burn dressing. ( a ) *Identification.* A hydrogel wound dressing is a sterile or non-sterile device intended to cover a wound, to absorb wound exudate, to control bleeding or fluid loss, and to protect against abrasion, friction, desiccation, and contamination. It consists of a nonresorbable matrix made of hydrophilic polymers or other material in combination with water (at least 50 percent) and capable of absorbing exudate. This classification does not include a hydrogel wound dressing that contains added drugs such as antimicrobial agents, added biologics such as growth factors, or is composed of materials derived from animal sources.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in part 807, subpart E of this chapter subject to the limitations in § 878.9.
[64 FR 53929, Oct. 5, 1999]
UN PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 11

- 1527

RICHARD BLAKE ,
Plaintiff

– Appellant ,

v.

BURGER KING CORP. ,
Defendant

- Appellee

.

Appeal from the United States Distric t Court for the Eastern District of Virginia , at Richmond

. Henry E. Hudson , District Judge. ( 3:10

- cv - 00675

- HEH )

Submitted : August 18, 2011 Decided: August 22, 2011

Before WILKINSON, DAVIS, and KEENAN , Circuit Judges.

Affirmed by un published per curiam opinion

.

Richard Blake, Appellant Pro Se. Tyler Brown, JACKSON LEWIS, LLP, Reston, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.2

PER CURIAM:

Richard Blake appeals the district court ’ s order

dismissin g his employment discrimination suit . We have reviewed
the record and find no reversible error. Accordingly, we affirm
for the reasons stated by the district court. Blake v. Burger
King Corp. , No. 3:10

- cv - 00675

- HEH (E.D. Va. Apr. 18, 2011) . We dispense with oral argument because the facts and legal
contentions are adequately presented in the materials before the
court and argument would not aid the decisional process.

AFFIRMED
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.6700 Anesthesia stool. ( a ) *Identification.* An anesthesia stool is a device intended for use as a stool for the anesthesiologist in the operating room.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9.
[47 FR 31142, July 16, 1982, as amended at 54 FR 25049, June 12, 1989; 66 FR 38796, July 25, 2001]
§ 524.402 Chlorhexidine. ( a ) *Specifications.* Each gram of ointment contains 10 milligrams chlorhexidine acetate.
( b ) *Sponsors.* See Nos. 054771 and 058829 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs, cats, and horses* — ( 1 ) *Indications for use.* For use as a topical antiseptic ointment for surface wounds.
( 2 ) *Limitations.* Do not use in horses intended for human consumption.
[72 FR 265, Jan. 4, 2007, as amended at 79 FR 10967, Feb. 27, 2014]
SUPREME COURT OF THE STATE OF NEW YORK

Appellate Division, Fourth Judicial Department

1075 

KA 11-01021 

PRESENT: SMITH, J.P., PERADOTTO, CARNI, VALENTINO, AND WHALEN, JJ. 

 

THE PEOPLE OF THE STATE OF NEW YORK, RESPONDENT, 

V MEMORANDUM AND ORDER

ROBERT J. COX, DEFENDANT-APPELLANT. 

 

TIMOTHY P. DONAHER, PUBLIC DEFENDER, ROCHESTER (DAVID R. JUERGENS OF

COUNSEL), FOR DEFENDANT-APPELLANT. 

SANDRA DOORLEY, DISTRICT ATTORNEY, ROCHESTER (NICOLE M. FANTIGROSSI OF

COUNSEL), FOR RESPONDENT. 

 

Appeal from a judgment of the Monroe County Court (Melchor E.

Castro, A.J.), rendered October 29, 2010. The judgment convicted

defendant, upon his plea of guilty, of criminal possession of a

controlled substance in the fourth degree. 

It is hereby ORDERED that the judgment so appealed from is

unanimously affirmed. 

Memorandum: Defendant appeals from a judgment convicting him

upon his plea of guilty of criminal possession of a controlled

substance in the fourth degree (Penal Law § 220.09 [1]). Defendant’s

contention regarding the voluntariness of his plea is not preserved

for our review because he did not move to withdraw his plea or to

vacate the judgment of conviction on that ground (see People v Rosado,

70 AD3d 1315, 1316, lv denied 14 NY3d 892). In any event, the record

demonstrates that defendant’s plea was knowing, voluntary and

intelligent (see People v Seeber, 4 NY3d 780, 781-782). 

Entered: November 8, 2013 Frances E. Cafarell

Clerk of the Court
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
SEPTEMBER 30, 1997 FORM 10Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<EXCHANGE-RATE>                                      1
<CASH>                                          27,374
<SECURITIES>                                    51,489
<RECEIVABLES>                                   10,144
<ALLOWANCES>                                       496
<INVENTORY>                                     16,032
<CURRENT-ASSETS>                               108,148
<PP&E>                                          21,531
<DEPRECIATION>                                  13,068
<TOTAL-ASSETS>                                 139,415
<CURRENT-LIABILITIES>                           38,264
<BONDS>                                          7,702
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           313
<OTHER-SE>                                      93,067
<TOTAL-LIABILITY-AND-EQUITY>                   139,415
<SALES>                                         67,239
<TOTAL-REVENUES>                                67,239
<CGS>                                           42,686
<TOTAL-COSTS>                                   67,868
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 933
<INCOME-PRETAX>                                  1,325
<INCOME-TAX>                                       129
<INCOME-CONTINUING>                              1,196
<DISCONTINUED>                                 (3,340)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     8,567
<EPS-PRIMARY>                                      .28
<EPS-DILUTED>                                      .28 
        

</TABLE>
# C_2015354EN.01003501.xml

| 26.10.2015 | EN | Official Journal of the European Union | C 354/35 |
| --- | --- | --- | --- |

26.10.2015

EN

Official Journal of the European Union

C 354/35

---

Judgment of the General Court of 10 September 2015 — Laverana v OHIM (BIO COMPLEXE DE PLANTES ENRICHI EN PROTÉINES PROPRE FABRICATION)

(Case T-569/14) (1)

1

((Community trade mark - Application for Community figurative mark BIO COMPLEXE DE PLANTES ENRICHI EN PROTÉINES PROPRE FABRICATION - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2015/C 354/40)

Language of the case: German

Parties

Parties

Applicant: Laverana GmbH & Co. KG (Wennigsen, Germany) (represented by: J. Wachinger, M. Zöbisch and D. Chatterjee, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 27 May 2014 (Case R 122/2014-4) concerning an application for registration of the figurative sign BIO COMPLEXE DE PLANTES ENRICHI EN PROTÉINES PROPRE FABRICATION as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Laverana GmbH & Co. KG to bear the costs. |
| --- | --- |

2.

Orders Laverana GmbH & Co. KG to bear the costs.

---

(1)  OJ C 361, 13.10.2014.

1

---
EXHIBIT 23.3

                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

      We hereby consent to the inclusion by incorporation by reference in the
Registration Statement on Form S-8 of BankFirst Corporation, of our report dated
January 22, 1998 on the 1997 consolidated financial statements of First Franklin
Bancshares, Inc.

                                           /s/ G.R. Rush & Company, P.C.
                                           -----------------------------
                                           G.R. Rush & Company, P.C.
# C_2015073EN.01003501.xml

| 2.3.2015 | EN | Official Journal of the European Union | C 73/35 |
| --- | --- | --- | --- |

2.3.2015

EN

Official Journal of the European Union

C 73/35

---

Order of the General Court of 6 January 2015 — St'art and Others v Commission

(Case T-36/14) (1)

(Action for annulment - ‘European Creative Industries Alliance’ Programme - ‘C-I Factor’ project aimed at introducing new instruments in order to promote funding for cultural and creative industries - Decision to end the project - Measure forming part of a purely contractual framework from which it is not separable - Inadmissibility)

(2015/C 073/45)

Language of the case: French

Parties

Applicants: St’art — Fonds d’investissement dans les entreprises culturelles (Mons, Belgium); Stichting Cultuur — Ondernemen (Amsterdam, Netherlands); and Angel Capital Innovations Ltd (London, United Kingdom) (represented by: L. Dehin and C. Brüls, avocats)

Defendant: European Commission (represented by: S. Delaude, J. Estrada de Solà and S. Lejeune, acting as Agents)

Re:

Action for annulation of, first, the Commission’s ‘implicit decision of unknown date’ aimed at ending the project ‘C-I Factor SI2.609157-2/G/ENT/CIP/11/C/N03C011’ and, therefore, ending the grant awarded to the consortium of which the applicants form part and, secondly, the ‘explicit decision confirming it’ adopted on 29 November 2013.

Operative part of the order

| 1. | The action is dismissed. |
| --- | --- |

1.

The action is dismissed.

| 2. | St’art — Fonds d’investissement dans les entreprises culturelles, Stichting Cultuur — Ondernemen and Angel Capital Innovations Ltd are ordered to bear their own costs as well as those incurred by the European Commission. |
| --- | --- |

2.

St’art — Fonds d’investissement dans les entreprises culturelles, Stichting Cultuur — Ondernemen and Angel Capital Innovations Ltd are ordered to bear their own costs as well as those incurred by the European Commission.

---

(1)  OJ C 135, 5.5.2014.

---
§ 573.310 Crambe meal, heat toasted. ( a ) The additive is the seed meal of *Crambe abyssinica* obtained after the removal of oil from the seed and hull. The oil may be removed by pre-press solvent extraction or by solvent extraction alone. The resulting seed meal is heat toasted.
( b ) The additive conforms to the following percent-by-weight specifications: moisture, not more than 11 percent; oil, not more than 4 percent; crude protein, not less than 24 percent; crude fiber, not more than 26 percent; glucosinolate calculated as epi-progoitrin, not more than 4 percent; goitrin, not more than 0.1 percent; nitrile calculated as 1-cyano-2-hydroxy-3-butene, not more than 1.4 percent. At least 50 percent of the nitrogen shall be soluble in 0.5 *M* sodium chloride. Myrosinase enzyme activity shall be absent.
( c ) The additive is used or intended for use in the feed of feedlot cattle as a source of protein in an amount not to exceed 4.2 percent of the total ration.
[46 FR 30082, June 5, 1981]
Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ViroPharma Incorporated (the Company) on Form
10-K for the period ending December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                                              
|------------------------------------------------------------------------------
|/s/ Michel de Rosen                                                           
|Michel de Rosen                                                               
|President, Chief Executive Officer and Chairman of the
Board of Directors     
|March 1, 2006                                                                 
|                                                                              
|/s/ Vincent J. Milano                                                         
|Vincent J. Milano                                                             
|Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer
|March 1, 2006